Description
Chemical Identity
Mazdutide is a synthetic dual GLP-1 and glucagon receptor agonist with the molecular formula C210H322N46O67 and a molecular weight of approximately 4,563.1 Da. Developed by Innovent Biologics and Eli Lilly under the designations IBI362 and LY3305677, Mazdutide is a 33-amino acid oxyntomodulin analog featuring an Aib (2-aminoisobutyric acid) substitution at position 2 for DPP-IV resistance and a C20 fatty diacid conjugation at Lys20 enabling albumin binding for extended half-life and once-weekly dosing.
Mazdutide is also known by the following designations: LY3305677, IBI362, and OXM-3.
| Property | Value |
|---|---|
| Molecular Formula | C210H322N46O67 |
| Molecular Weight | 4,563.1 Da |
| CAS Number | 2259884-03-0 |
| Sequence | 33 aa oxyntomodulin analog with C20 fatty diacid |
| Research Status | Approved (China) |
Research Overview
Mazdutide has been investigated in Phase 3 clinical trials for obesity and type 2 diabetes. The dual mechanism of action combines GLP-1 receptor agonism for appetite suppression, enhanced insulin secretion, and gastric emptying delay with glucagon receptor agonism for increased hepatic lipid oxidation, thermogenesis, and energy expenditure. As an oxyntomodulin analog, Mazdutide engages both receptors through a single peptide molecule, mimicking the endogenous gut hormone that naturally activates both pathways.
Key areas of published research include:
- GLORY Phase 3 Trial (Obesity): The pivotal GLORY trial in Chinese adults with obesity or overweight, published in the New England Journal of Medicine, demonstrated dose-dependent weight loss with Mazdutide. The 4 mg dose achieved -10.09% weight loss at week 48, the 6 mg dose achieved -12.55%, and the 9 mg dose achieved up to -20.1% weight loss at week 60. Approximately 73.9-82.0% of participants in the 4-6 mg groups achieved at least 5% weight loss. These results supported Chinese regulatory approval in June 2025.
- Type 2 Diabetes Trials: In patients with type 2 diabetes and obesity, Mazdutide demonstrated significant HbA1c reductions of up to -2.15% versus placebo alongside substantial weight loss, supporting dual metabolic benefit for patients with both conditions.
- Dual Agonist Mechanism: The glucagon receptor agonism component differentiates Mazdutide from pure GLP-1 agonists by enhancing energy expenditure and hepatic fat metabolism. This dual action has shown particular promise for liver fat reduction, positioning Mazdutide as a potential candidate for metabolic dysfunction-associated steatohepatitis research.
Mazdutide was approved in China in June 2025 for weight management. It remains investigational in the United States and Europe.
Specifications
All Mazdutide supplied by Prescott Bio Canada is manufactured to research-grade standards.
| Specification | Detail |
|---|---|
| Purity | >98% (HPLC) |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Storage (lyophilized) | -20°C, protected from light |
| Storage (reconstituted) | 2-8°C, use within 30 days |
| Solubility | Soluble in bacteriostatic water, sterile water, or normal saline |
Each vial is accompanied by a Certificate of Analysis (COA) documenting purity, identity, and endotoxin testing.
Research Applications
Mazdutide is supplied exclusively for in vitro and in vivo laboratory research. Published experimental applications include:
- Investigation of dual GLP-1/glucagon receptor co-agonism and synergistic metabolic effects
- Study of oxyntomodulin-based peptide engineering and C20 fatty diacid conjugation strategies
- Examination of hepatic lipid metabolism, thermogenesis, and energy expenditure through glucagon signaling
- Research into incretin-based combination approaches for obesity and type 2 diabetes
Researchers should consult the primary literature and institutional review protocols before designing experiments with Mazdutide.
Storage and Handling
Lyophilized powder: Store at -20°C in the original sealed vial, protected from light and moisture. Under these conditions, Mazdutide maintains stability for up to 24 months.
Reconstituted solution: Reconstitute with bacteriostatic water or sterile water to the desired concentration. Store reconstituted Mazdutide at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles.
Handling precautions: This product is intended for research use only (RUO). Not for human or veterinary diagnostic or therapeutic use. Handle using standard laboratory safety practices including appropriate PPE.